Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

Core Viewpoint - Liquidia Corporation is set to report its full year 2024 financial results on March 19, 2025, and will host a live webcast to discuss these results and provide a corporate update [1]. Company Overview - Liquidia Corporation is a biopharmaceutical company focused on developing innovative therapies for patients with rare cardiopulmonary diseases [3]. - The company is currently developing and commercializing products for pulmonary hypertension using its proprietary PRINT® Technology [3]. - Liquidia's lead candidate is YUTREPIA™ (treprostinil) inhalation powder, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) [3]. - The company is also working on L606, a sustained-release formulation of treprostinil, and markets generic Treprostinil Injection for PAH treatment [3].